ANZGOG ASM 2025

PURE SCIENCE SYMPOSIUM – WEDNESDAY 5 MARCH – Chairs: Kylie Gorringe, Pamela Pollock, Nicola Meagher

Federation Ballroom North

Session 1 – Endometrial and ovarian cancer Chair: Pamela Pollock

11:00 AM – 12:30 PM

Speakers

Bradley Djirabidj Bell, Bryony Simcock and Pamela Pollock

11:00 AM

Welcome to Country, Acknowledgement, & Session introduction

11:05 AM

Using big data to find solutions to endometrial cancer prevention – how effective are weight loss treatments?

Susan Jordan

11:25 AM

Methylated circulating tumour DNA for detection of adenocarcinomas

Jean Winter

Defective chromatin remodelling present in less commonly diagnosed chemo-resistant ovarian cancer subtypes and in endometriosis, may reveal new therapeutic opportunities for these conditions Abstract 1: Targeting ARID1B in ARID1A-mutant Ovarian Clear Cell Carcinoma: A comprehensive drug repurposing approach combining in silico screening and in vitro validation

11:45 AM

Deborah Marsh

12:00 PM

Amani Alghalayini

12:15 PM

Abstract 2: Gene Expression Profiles to Predict Residual Disease After Cytoreductive Surgery for Ovarian Cancer

Brittney Harrington

LUNCH – The Atrium

12:30 PM

Session 2 – Ovarian cancer Chair: Kylie Gorringe

11:00 AM – 3:35 PM

Speakers

Multimodal Spatial Profiling Reveals Immune Suppression and Microenvironment Remodeling in Fallopian Tube Precursors to High-Grade Serous Ovarian Carcinoma Tumour-infiltrating B cells: the secret weapon promoting long-term survival in high-grade serous ovarian cancer?

1:30 PM

Tanjina Kader

1:50 PM

Dale Garsed

2:10 PM

Triggering an Anti-Tumour Immune Response in High-Grade Serous Ovarian Cancer

Jenny Zeng

2:30 PM

Towards a target for molecular imaging and treatment of epithelial ovarian cancers

John Hooper

Abstract 3: Deciphering chemotherapy resistance mechanisms in mucinous ovarian cancer via barcode clonal tracking Abstract 4: Novel preclinical models of ovarian carcinosarcoma enable the identification of potential effective combination therapies for future clinical benefit Abstract 5: Identification of potential therapeutic options to target the rare ovarian cancer subtype: Small-cell carcinoma of the ovary, hypercalcemic type

2:50 PM

Suad Abdirahman

3:05 PM

Holly Barker

3:20 PM

Natisha Field

AFTERNOON TEA – The Atrium and Canberra Room

3:35 PM

Session 3 - Cervical and rare gynaecological cancers Chair: Nicola Meagher

11:00 AM – 5:30 PM

Speakers

High throughput discovery of synergistic drug combinations for the treatment of Low Grade Serous Ovarian Carcinoma

4:00 PM

Kathleen Pishas

4:20 PM

Cervical cancer epidemiology – from data to policy

Megan Smith

4:40 PM

Immune markers of persistence and regression in cervical neoplasia

Merilyn Hibma

Abstract 6: Mapping the complexity of low-grade serous ovarian carcinoma through whole-genome and transcriptome sequencing

5:00 PM

Tania Moujaber

5:15 PM

Rapid Fire Abstract 1: Targeting the nucleoli as a strategy to treat ovarian cancer

Shalini Chelliah

Rapid Fire Abstract 2: Mutation profiling and molecular analysis in the INOVATe study: towards a personalised approach to the management of ovarian cancer patients

5:20 PM

Natalie Bouantoun

5:25 PM

Rapid Fire Abstract 3: Uncovering mechanisms of PARP inhibitor resistance in high-grade serous ovarian cancer

Zoe Phan

POSTER SESSION The Gallery Room Chair: Michelle Harrison WELCOME RECEPTION The Atrium

Sponsored by:

5:30 PM

6:30 PM – 8:30 PM

Sponsored by:

*Program subject to change.

5